Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Br J Radiol ; 89(1063): 20160093, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27074624

RESUMO

OBJECTIVE: To investigate brain radiation dose in complex cases arising from two stereotactic linear accelerator designs and to present a method for comparing brain dose to published data. METHODS: Two head designs were considered: Beam Modulator (BM) and Agility (AG). 12 patients treated on BM were replanned with AG. Planning objectives were: minimize brain dose and satisfy target coverage and organs at risk dose constraints. Each of the 36 targets was analyzed for conformality index (CI Paddick), gradient index (GI) and homogeneity index (HI). Total volume of tissue receiving 80% (V80) of the prescription dose down to 25% (V25) was evaluated. Similarly the volume of brain minus planning target volume receiving 80% (BMP80) down to 25% (BMP25) was evaluated. The mean brain dose and BMP dose were also evaluated. System differences were statistically evaluated using Wilcoxon signed-rank test. Power-law models for total volume (V) and brain minus planning target volumes (BMP) were generated based on BM data. RESULTS: The median CI Paddick was 0.74 and 0.76 for BM and AG, respectively (p = 0.04). The median GI was 5.5 and 6.1 (p < 0.01) and the median HI was 1.17 and 1.16 for BM and AG, respectively (p < 0.01). Neither V or BMP receiving doses of 80% down to 40% exhibited statistically significant difference between the two systems, whereas the volume of brain minus PTV receiving 25% (BMP25) was weakly different (p = 0.02). AG exhibited a lower mean BMP dose (4.1 Gy) than BM (4.6 Gy) (p < 0.01). Power-law models for V/BMP showed excellent (R(2) > 0.80) agreement for the dose levels studied and comparable results with published data. CONCLUSION: Treatment plans of equivalent quality were attained with AG compared with BM. ADVANCES IN KNOWLEDGE: The AG system involves a novel collimation design. The present article demonstrates equivalent or improved brain dose for complex, multitarget cases using AG vs an older stereotactic system.


Assuntos
Neoplasias Encefálicas/radioterapia , Aceleradores de Partículas , Hipofracionamento da Dose de Radiação , Radioterapia de Intensidade Modulada/instrumentação , Encéfalo , Neoplasias Encefálicas/secundário , Humanos , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Radioterapia de Intensidade Modulada/métodos
2.
Dis Model Mech ; 7(3): 363-72, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24487407

RESUMO

Tumor radiation resistance poses a major obstacle in achieving an optimal outcome in radiation therapy. In the current study, we characterize a novel therapeutic approach that combines ultrasound-driven microbubbles with radiation to increase treatment responses in a prostate cancer xenograft model in mice. Tumor response to ultrasound-driven microbubbles and radiation was assessed 24 hours after treatment, which consisted of radiation treatments alone (2 Gy or 8 Gy) or ultrasound-stimulated microbubbles only, or a combination of radiation and ultrasound-stimulated microbubbles. Immunohistochemical analysis using in situ end labeling (ISEL) and terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) revealed increased cell death within tumors exposed to combined treatments compared with untreated tumors or tumors exposed to radiation alone. Several biomarkers were investigated to evaluate cell proliferation (Ki67), blood leakage (factor VIII), angiogenesis (cluster of differentiation molecule CD31), ceramide-formation, angiogenesis signaling [vascular endothelial growth factor (VEGF)], oxygen limitation (prolyl hydroxylase PHD2) and DNA damage/repair (γH2AX). Results demonstrated reduced vascularity due to vascular disruption by ultrasound-stimulated microbubbles, increased ceramide production and increased DNA damage of tumor cells, despite decreased tumor oxygenation with significantly less proliferating cells in the combined treatments. This combined approach could be a feasible option as a novel enhancing approach in radiation therapy.


Assuntos
Microbolhas , Neoplasias da Próstata/radioterapia , Ultrassom , Ensaios Antitumorais Modelo de Xenoenxerto , Animais , Biomarcadores Tumorais/metabolismo , Morte Celular , Hipóxia Celular , Linhagem Celular Tumoral , Proliferação de Células , Sobrevivência Celular , Ceramidas/metabolismo , Dano ao DNA , Humanos , Prolina Dioxigenases do Fator Induzível por Hipóxia/metabolismo , Imuno-Histoquímica , Marcação In Situ das Extremidades Cortadas , Antígeno Ki-67/metabolismo , Masculino , Camundongos SCID , Modelos Biológicos , Neovascularização Patológica/metabolismo , Neovascularização Patológica/patologia , Oxigênio/metabolismo , Molécula-1 de Adesão Celular Endotelial a Plaquetas/metabolismo , Neoplasias da Próstata/irrigação sanguínea , Neoplasias da Próstata/patologia , Transdução de Sinais , Fator A de Crescimento do Endotélio Vascular/metabolismo
3.
Ultrasound Med Biol ; 39(11): 1983-90, 2013 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-23993051

RESUMO

Tumor responses to high-dose (>8 Gy) radiation therapy are tightly connected to endothelial cell death. In the study described here, we investigated whether ultrasound-activated microbubbles can locally enhance tumor response to radiation treatments of 2 and 8 Gy by mechanically perturbing the endothelial lining of tumors. We evaluated vascular changes resulting from combined microbubble and radiation treatments using high-frequency 3-D power Doppler ultrasound in a breast cancer xenograft model. We compared treatment effects and monitored vasculature damage 3 hours, 24 hours and 7 days after treatment delivery. Mice treated with 2 Gy radiation and ultrasound-activated microbubbles exhibited a decrease in vascular index to 48 ± 10% at 24 hours, whereas vascular indices of mice treated with 2 Gy radiation alone or microbubbles alone were relatively unchanged at 95 ± 14% and 78 ± 14%, respectively. These results suggest that ultrasound-activated microbubbles enhance the effects of 2 Gy radiation through a synergistic mechanism, resulting in alterations of tumor blood flow. This novel therapy may potentiate lower radiation doses to preferentially target endothelial cells, thus reducing effects on neighboring normal tissue and increasing the efficacy of cancer treatments.


Assuntos
Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/radioterapia , Fluorocarbonos/uso terapêutico , Ablação por Ultrassom Focalizado de Alta Intensidade/métodos , Imageamento Tridimensional/métodos , Animais , Linhagem Celular Tumoral , Terapia Combinada , Meios de Contraste/uso terapêutico , Humanos , Camundongos , Camundongos Nus , Microbolhas/uso terapêutico , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Resultado do Tratamento , Ultrassonografia
4.
Transl Oncol ; 6(1): 17-24, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23418613

RESUMO

PURPOSE: Ultrasound elastography is a new imaging technique that can be used to assess tissue stiffness. The aim of this study was to investigate the potential of ultrasound elastography for monitoring treatment response of locally advanced breast cancer patients undergoing neoadjuvant therapy. METHODS: Fifteen women receiving neoadjuvant chemotherapy had the affected breast scanned before, 1, 4, and 8 weeks following therapy initiation, and then before surgery. Changes in elastographic parameters related to tissue biomechanical properties were then determined and compared to clinical and pathologic tumor response after mastectomy. RESULTS: Patients who responded to therapy demonstrated a significant decrease (P < .05) in strain ratios and strain differences 4 weeks after treatment initiation compared to non-responding patients. Mean strain ratio and mean strain difference for responders was 81 ± 3% and 1 ± 17% for static regions of interest (ROIs) and 81 ± 3% and 6 ± 18% for dynamic ROIs, respectively. In contrast, these parameters were 102±2%, 110±17%, 101±4%, and 109±30% for non-responding patients, respectively. Strain ratio using static ROIs was found to be the best predictor of treatment response, with 100% sensitivity and 100% specificity obtained 4 weeks after starting treatment. CONCLUSIONS: These results suggest that ultrasound elastography can be potentially used as an early predictor of tumor therapy response in breast cancer patients.

5.
Clin Cancer Res ; 19(8): 2163-74, 2013 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-23426278

RESUMO

PURPOSE: Quantitative ultrasound techniques have been recently shown to be capable of detecting cell death through studies conducted on in vitro and in vivo models. This study investigates for the first time the potential of early detection of tumor cell death in response to clinical cancer therapy administration in patients using quantitative ultrasound spectroscopic methods. EXPERIMENTAL DESIGN: Patients (n = 24) with locally advanced breast cancer received neoadjuvant chemotherapy treatments. Ultrasound data were collected before treatment onset and at 4 times during treatment (weeks 1, 4, and 8, and preoperatively). Quantitative ultrasound parameters were evaluated for clinically responsive and nonresponding patients. RESULTS: Results indicated that quantitative ultrasound parameters showed significant changes for patients who responded to treatment, and no similar alteration was observed in treatment-refractory patients. Such differences between clinically and pathologically determined responding and nonresponding patients were statistically significant (P < 0.05) after 4 weeks of chemotherapy. Responding patients showed changes in parameters related to cell death with, on average, an increase in mid-band fit and 0-MHz intercept of 9.1 ± 1.2 dBr and 8.9 ± 1.9 dBr, respectively, whereas spectral slope was invariant. Linear discriminant analysis revealed a sensitivity of 100% and a specificity of 83.3% for distinguishing nonresponding patients by the fourth week into a course of chemotherapy lasting several months. CONCLUSION: This study reports for the first time that quantitative ultrasound spectroscopic methods can be applied clinically to evaluate cancer treatment responses noninvasively. The results form a basis for monitoring chemotherapy effects and facilitating the personalization of cancer treatment.


Assuntos
Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/tratamento farmacológico , Avaliação de Resultados em Cuidados de Saúde/métodos , Adulto , Idoso , Neoplasias da Mama/patologia , Morte Celular/efeitos dos fármacos , Quimioterapia Adjuvante , Feminino , Humanos , Pessoa de Meia-Idade , Terapia Neoadjuvante , Reprodutibilidade dos Testes , Fatores de Tempo , Ultrassonografia
6.
Transl Oncol ; 5(4): 238-46, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22937175

RESUMO

The aim of this study was to investigate the potential of diffuse optical spectroscopy for monitoring of patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. Fifteen women receiving treatment for LABC had the affected breast scanned before; 1 week, 4 weeks, and 8 weeks after treatment initiation; and before surgery. Optical properties related to tissue microstructure and biochemical composition were obtained. Clinical and pathologic tumor response was evaluated using whole-mount pathology after mastectomy. Patients who responded to treatment demonstrated an initial increase followed by a drop in optical parameters measured in the whole breast, whereas nonresponding patients demonstrated only a drop in the same parameters 1 week after treatment initiation. Responding patients demonstrated a significant increase of 17% ± 7%, 8% ± 8%, 10% ± 7%, 11% ± 11%, and 16% ± 15% in deoxygenated hemoglobin, oxygenated hemoglobin, total hemoglobin concentrations, water percentage, and tissue optical index, 1 week after treatment initiation, respectively. In contrast, nonresponding patients had a decrease of 14% ± 9%, 18% ± 7%, 17% ± 7%, 29% ± 7%, and 32% ± 9% in their corresponding optical parameters. Deoxygenated hemoglobin concentration (with 100% sensitivity, 83% specificity) and water percentage (with 75% sensitivity, 100% specificity) were found to be the best predictors of treatment response at 1 week after starting treatment. The results of this study suggest that optical parameters can be potentially used to predict and monitor patients' responses to neoadjuvant chemotherapy and can form a basis for the customization of treatments in which inefficacious treatments can be switched to more efficacious therapies.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...